» Articles » PMID: 26406987

Molecular Basis of in Vitro Affinity Maturation and Functional Evolution of a Neutralizing Anti-human GM-CSF Antibody

Overview
Journal MAbs
Date 2015 Sep 26
PMID 26406987
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

X-ray structure analysis of 4 antibody Fab fragments, each in complex with human granulocyte macrophage colony stimulating factor (GM-CSF), was performed to investigate the changes at the protein-protein binding interface during the course of in vitro affinity maturation by phage display selection. The parental antibody MOR03929 was compared to its derivatives MOR04252 (CDR-H2 optimized), MOR04302 (CDR-L3 optimized) and MOR04357 (CDR-H2 and CDR-L3 optimized). All antibodies bind to a conformational epitope that can be divided into 3 sub-epitopes. Specifically, MOR04357 binds to a region close to the GM-CSF N-terminus (residues 11-24), a short second sub-epitope (residues 83-89) and a third at the C-terminus (residues 112-123). Modifications introduced during affinity maturation in CDR-H2 and CDR-L3 led to the establishment of additional hydrogen bonds and van der Waals contacts, respectively, providing a rationale for the observed improvement in binding affinity and neutralization potency. Once GM-CSF is complexed to the antibodies, modeling predicts a sterical clash with GM-CSF binding to GM-CSF receptor α and β chain. This predicted mutually exclusive binding was confirmed by a GM-CSF receptor α chain ligand binding inhibition assay. Finally, high throughput sequencing of clones obtained after affinity maturation phage display pannings revealed highly selected consensus sequences for CDR-H2 as well for CDR-L3, which are in accordance with the sequence of the highest affinity antibody MOR04357. The resolved crystal structures highlight the criticality of these strongly selected residues for high affinity interaction with GM-CSF.

Citing Articles

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X).

Weinblatt M, Taylor P, McInnes I, Atsumi T, Strand V, Takeuchi T BMJ Open. 2025; 15(3):e088869.

PMID: 40044198 PMC: 11883618. DOI: 10.1136/bmjopen-2024-088869.


Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).

Fleischmann R, van der Heijde D, Strand V, Atsumi T, McInnes I, Takeuchi T Ann Rheum Dis. 2023; 82(12):1516-1526.

PMID: 37699654 PMC: 10646845. DOI: 10.1136/ard-2023-224482.


Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).

Taylor P, Weinblatt M, McInnes I, Atsumi T, Strand V, Takeuchi T Ann Rheum Dis. 2023; 82(12):1527-1537.

PMID: 37696589 PMC: 10646837. DOI: 10.1136/ard-2023-224449.


Neutralizing GM-CSF autoantibodies in pulmonary alveolar proteinosis, cryptococcal meningitis and severe nocardiosis.

Salvator H, Cheng A, Rosen L, Williamson P, Bennett J, Kashyap A Respir Res. 2022; 23(1):280.

PMID: 36221098 PMC: 9552154. DOI: 10.1186/s12931-022-02103-9.


Qualitative and psychometric approaches to evaluate the PROMIS pain interference and sleep disturbance item banks for use in patients with rheumatoid arthritis.

Becker B, Raymond K, Hawkes C, Mitchell Foster A, Lovley A, Saucier C J Patient Rep Outcomes. 2021; 5(1):52.

PMID: 34228217 PMC: 8260648. DOI: 10.1186/s41687-021-00318-w.


References
1.
Hamilton J, Tak P . The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. Arthritis Rheum. 2009; 60(5):1210-21. DOI: 10.1002/art.24505. View

2.
Waterhouse A, Procter J, Martin D, Clamp M, Barton G . Jalview Version 2--a multiple sequence alignment editor and analysis workbench. Bioinformatics. 2009; 25(9):1189-91. PMC: 2672624. DOI: 10.1093/bioinformatics/btp033. View

3.
Blech M, Seeliger D, Kistler B, Bauer M, Hafner M, Horer S . Molecular structure of human GM-CSF in complex with a disease-associated anti-human GM-CSF autoantibody and its potential biological implications. Biochem J. 2012; 447(2):205-15. DOI: 10.1042/BJ20120884. View

4.
Gasson J, Kaufman S, Weisbart R, Tomonaga M, Golde D . High-affinity binding of granulocyte-macrophage colony-stimulating factor to normal and leukemic human myeloid cells. Proc Natl Acad Sci U S A. 1986; 83(3):669-73. PMC: 322925. DOI: 10.1073/pnas.83.3.669. View

5.
Cook A, Braine E, Campbell I, Rich M, Hamilton J . Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res. 2001; 3(5):293-8. PMC: 64841. DOI: 10.1186/ar318. View